Title | AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R |
Journal | Nat Commun |
Volume | 9 |
Issue | 1 |
Pagination | 222 |
Date Published | 2018 Jan 15 |
ISSN | 2041-1723 |
Keywords | Animals, B-Lymphocytes, Cytidine Deaminase, Epigenesis, Genetic, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Germinal Center, Humans, Lymphoma, Large B-Cell, Diffuse, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Mutation |
Abstract | <p>Epigenetic heterogeneity is emerging as a feature of tumors. In diffuse large B-cell lymphoma (DLBCL), increased cytosine methylation heterogeneity is associated with poor clinical outcome, yet the underlying mechanisms remain unclear. Activation-induced cytidine deaminase (AICDA), an enzyme that mediates affinity maturation and facilitates DNA demethylation in germinal center (GC) B cells, is required for DLBCL pathogenesis and linked to inferior outcome. Here we show that AICDA overexpression causes more aggressive disease in BCL2-driven murine lymphomas. This phenotype is associated with increased cytosine methylation heterogeneity, but not with increased AICDA-mediated somatic mutation burden. Reciprocally, the cytosine methylation heterogeneity characteristic of normal GC B cells is lost upon AICDA depletion. These observations are relevant to human patients, since DLBCLs with high AICDA expression manifest increased methylation heterogeneity vs. AICDA-low DLBCLs. Our results identify AICDA as a driver of epigenetic heterogeneity in B-cell lymphomas with potential significance for other tumors with aberrant expression of cytidine deaminases.</p> |
DOI | 10.1038/s41467-017-02595-w |
Alternate Journal | Nat Commun |
PubMed ID | 29335468 |
PubMed Central ID | PMC5768781 |
Grant List | P30 CA008748 / CA / NCI NIH HHS / United States R01 CA194547 / CA / NCI NIH HHS / United States |